DRKS00016696招募中3 期
Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1.history of repeatedly occurring episodes of heartburn with first manifestation at least 6 months ago
- •2.repeatedly occurring episodes of heartburn on at least 2 days per week within each of the last 4 weeks prior to screening visit
- •3.RDQ score of = 8 in the dimension heartburn considering the last 7 days prior to screening visit
- •4.availability of results of a gastric endoscopy within 12 months before screening visit excluding relevant erosive disease (reflux esophagitis), i.e. assessment according to Los Angeles Classification not higher than grade A, and other severe gastrointestinal diseases including malignancies, ulcer, Barett's oesophagus, and oesophageal varices
- •5.age: 18 years or older
- •6.willing and able to ingest at least 1.5 L water per day during the course of the trial
- •7.willing not to change general eating habits for the duration of the trial, i.e. no special diet planned
- •8.written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the patients participating in the clinical trial Furthermore, at baseline visit:
- •9.RDQ score of = 8 in the dimension heartburn considering the last 7 days prior to baseline visit
- •10.intake of at least 1.5 L water or other beverages per day on at least 10 days over the last 14 days prior to baseline visit
排除标准
- •Safety concerns
- •1.symptoms occurring after the time of gastric endoscopic examination:
- •a)difficulty in swallowing (dysphagia) or painful swallowing (odynophagia)
- •b)non-intended weight loss = 5 % of body weight
- •c)iron deficiency anaemia
- •d)experiencing episodes of persistent vomiting (at least 7 to 10 days of protracted vomiting) without causal explanation like GI virus infection
- •2.signs of moderate or severe renal impairment known from medical history or reported during screening examination
- •3.severe heart failure (i.e. NYHA III/IV)
- •4.known Zollinger Ellison syndrome
- •5.active or known inflammatory bowel diseases (e.g. colitis ulcerosa, Crohn´s disease) or other severe chronic intestinal disease (e.g. colonic stenosis)
- •6.diagnosed irritable bowel syndrome
- •7.patients, who rely on regular intake of medicines with pH-dependent absorption (i.e. HIV protease inhibitors, tyrosine kinase inhibitors)
- •8.known calcaemia (e.g. as a result of hyperparathyroidis, vitamine D overdose, paraneoplastic syndrome)
- •9.known nephrolithiasis due to calcium-containing kidney stones
- •10.known hypophosphatemia
- •11.known hypercalciuria
- •12.known hereditary problems of fructose intolerance, glucose-galactose malabsorption or saccharase isomaltase deficiency
- •13.patients with severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
- •Lack of suitability for the clinical trial
- •14.history of surgical intervention at oesophagus or gastric and jejunal area
- •15.known or suspected drug or alcohol abuse within the last year
- •16.known or suspected eating disorders (e.g. bulimia)
- •17.continuous treatment with nonsteroidal anti-inflammatory drugs (NSAIDs e.g. piroxicam, ketoprofen, diclofenac, acetylsalicylic acid or indomethacin (occasionally treatment with NSAIDs or ASS 100 mg daily is permitted))
- •18.use of PPIs within 4 weeks prior to screening visit
- •19.participation in a clinical trial during the last 30 days prior to individual enrolment of the patient
- •For female patients with childbearing potential only:
- •20.positive pregnancy test at screening examination
- •21.pregnant women
- •22.female patients who do not agree to apply highly effective contraceptive methods
- •Administrative reasons
- •23.patients suspected or known not to follow instructions especially with regard to drinking habits and general eating habits during the study
- •24.patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
- •25.patients with close affiliation with the sponsor or the investigational site; e.g. close relative of the investigator or a dependent person (e.g. employee)
- •Furthermore, at baseline visit:
- •26.moderate renal impairment (i.e. eGFR = 59 mL/min/1.73 m2 determined from serum creatinine during screening)
- •27.laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator or if the following thresholds have been reached
- •- haemoglobin < 6.2 mmol/l
- •- leukocytes <2500 / µl
- •- platelets < 60000 / µl
- •28.use of PPIs within 4 weeks prior to baseline visit (during run-in period)
- •29.use of H2-receptor antagonists, prokinetics, healing waters or antacids other than the rescue medication within 2 weeks prior to baseline visit (during run-in period)
研究者
相似试验
进行中（未招募）
1 期
Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placeboEfficacy and tolerability investigations of a healing water in symptomatic treatment of heartburnMedDRA version: 20.0Level: LLTClassification code 10019326Term: HeartburnSystem Organ Class: 100000004856EUCTR2017-001100-30-DEFachingen Heil- und Mineralbrunnen GmbH150
尚未招募
Unknown
Soft capsules with ozonated sunflower oil versus oral OLEOZON® in patients with GiardiosisGiardiosisRPCEC00000440ational Centre for Scientific Research (CNIC)200
尚未招募
3 期
Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptomsGastrointestinal symptomsSigns and Symptoms, DigestiveDigestive System DiseasesRPCEC00000372ational Centre for Scientific Research100
已完成
3 期
Study to evaluate the efficacy and tolerability of Pegfilgrastim in chemotherapy induced neutropeniaCTRI/2009/091/000579GENNOVA BIOPHARMACEUTICALS LTD
已完成
3 期
Study to evaluate the efficacy and tolerability of Filgrastim in chemotherapy induced neutropeniaCTRI/2009/091/000574GENNOVA BIOPHARMACEUTICALS LTD